DE60222856D1 - Endotoxin-bindung durch milchsäurebakterien und bifidobacteria - Google Patents

Endotoxin-bindung durch milchsäurebakterien und bifidobacteria

Info

Publication number
DE60222856D1
DE60222856D1 DE60222856T DE60222856T DE60222856D1 DE 60222856 D1 DE60222856 D1 DE 60222856D1 DE 60222856 T DE60222856 T DE 60222856T DE 60222856 T DE60222856 T DE 60222856T DE 60222856 D1 DE60222856 D1 DE 60222856D1
Authority
DE
Germany
Prior art keywords
bifidobacteria
acid bacteria
endotoxin binding
milky acid
milky
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222856T
Other languages
English (en)
Other versions
DE60222856T2 (de
Inventor
Eduardo Schiffrin
Guillermo Kociubinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8179863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60222856(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of DE60222856D1 publication Critical patent/DE60222856D1/de
Application granted granted Critical
Publication of DE60222856T2 publication Critical patent/DE60222856T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/854—Lactobacillus acidophilus
DE60222856T 2001-02-06 2002-02-01 Endotoxin-bindung durch milchsäurebakterien und bifidobacteria Expired - Lifetime DE60222856T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200436 2001-02-06
EP01200436 2001-02-06
PCT/EP2002/001163 WO2002062360A1 (en) 2001-02-06 2002-02-01 Endotoxin binding by lactic acid bacteria and bifidobacteria

Publications (2)

Publication Number Publication Date
DE60222856D1 true DE60222856D1 (de) 2007-11-22
DE60222856T2 DE60222856T2 (de) 2008-07-24

Family

ID=8179863

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222856T Expired - Lifetime DE60222856T2 (de) 2001-02-06 2002-02-01 Endotoxin-bindung durch milchsäurebakterien und bifidobacteria

Country Status (21)

Country Link
US (2) US7550285B2 (de)
EP (1) EP1359924B1 (de)
JP (3) JP2004531477A (de)
KR (1) KR100845456B1 (de)
CN (1) CN1250232C (de)
AT (1) ATE375164T1 (de)
AU (1) AU2002250886B2 (de)
BR (1) BR0207019A (de)
CA (1) CA2436264C (de)
DE (1) DE60222856T2 (de)
EA (1) EA006397B1 (de)
ES (1) ES2292744T3 (de)
HK (1) HK1066174A1 (de)
IL (1) IL157071A0 (de)
MX (1) MXPA03007024A (de)
NO (1) NO20033372L (de)
NZ (1) NZ527493A (de)
PL (1) PL367083A1 (de)
PT (1) PT1359924E (de)
WO (1) WO2002062360A1 (de)
ZA (1) ZA200306935B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157071A0 (en) * 2001-02-06 2004-02-08 Nestle Sa Endotoxine binding by lactic acid bacteria and bifidobacteria
US7179460B2 (en) * 2002-12-05 2007-02-20 Danisco A/S Bacterial composition and its use
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
AR053805A1 (es) 2005-05-31 2007-05-23 Iams Company Bifidobacterias probioticas para felinos
US20090083067A1 (en) * 2006-03-29 2009-03-26 Mary Elaine Freeland Methods and kits for selecting a health care product
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
MY151892A (en) * 2007-02-28 2014-07-14 Mjn Us Holdings Llc Product containing inactivated probiotic for infants
KR100913406B1 (ko) * 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ１－매개 면역 질환의 예방 또는 치료용 조성물
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
PL2459203T3 (pl) * 2009-07-30 2019-04-30 Dupont Nutrition Biosci Aps Bakterie kwasu mlekowego i bifidobakterie do leczenia endotoksemii
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011069860A1 (en) 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
JP2010280664A (ja) * 2010-07-02 2010-12-16 Biogaia Ab ラクトバチルス・リューテリ（Ｌａｃｔｏｂａｃｉｌｌｕｓｒｅｕｔｅｒｉ）株を用いる哺乳類における免疫機能の改善方法
US20140234487A1 (en) 2011-07-13 2014-08-21 Friesland Brands B.V. Dairy based compositions with low lps
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
CA2923236C (en) * 2013-09-30 2019-06-04 Elc Management Llc Watery lotion skin care compositions and methods
CN108064132A (zh) 2014-10-31 2018-05-22 霍勒拜欧姆公司 与病症的微生物治疗和诊断有关的方法和组合物
CN104498375B (zh) * 2014-12-02 2017-05-10 江南大学 一株具有内毒素吸附特性的耶氏酵母及其吸附特性研究方法
JP6710075B2 (ja) * 2016-03-29 2020-06-17 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
TWI640319B (zh) * 2017-05-12 2018-11-11 健茂生物科技股份有限公司 具有抗發炎活性之醱酵液的製備方法
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
JP6888145B2 (ja) * 2020-03-23 2021-06-16 カゴメ株式会社 Ｌｐｓ産生抑制剤、及びｌｐｓ産生抑制用の食品組成物
WO2021253017A2 (en) * 2020-06-07 2021-12-16 Ramasamy Sundaram Compositions and methods for detoxifying bacterial endotoxins and hydrogen sulfide by recombinant fusion enzymes
US20230323332A1 (en) 2020-08-28 2023-10-12 Chr. Hansen A/S Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555618A (en) * 1896-03-03 Hay-loader
IT1254210B (it) * 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
JP2506314B2 (ja) * 1993-10-27 1996-06-12 全国農業協同組合連合会 家禽・豚の敗血症の予防・治療剤及び飼料
US6506389B2 (en) * 1995-10-20 2003-01-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
ES2164299T5 (es) * 1997-01-09 2009-03-01 Societe Des Produits Nestle S.A. Producto cereal que contiene probioticos.
JP4163276B2 (ja) * 1998-02-05 2008-10-08 独立行政法人理化学研究所 機能性組成物
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
PL348973A1 (en) * 1998-12-11 2002-06-17 Urex Biotech Inc Oral administration of lactobacillus for the treatment and prevention of urogenital infection
EP1276488B1 (de) * 2000-03-24 2006-12-20 Societe Des Produits Nestle S.A. Milchsäurebakterium zur prävention der bauchfellentzündung
IL157071A0 (en) * 2001-02-06 2004-02-08 Nestle Sa Endotoxine binding by lactic acid bacteria and bifidobacteria

Also Published As

Publication number Publication date
KR100845456B1 (ko) 2008-07-10
US7550285B2 (en) 2009-06-23
PL367083A1 (en) 2005-02-21
JP2004531477A (ja) 2004-10-14
CA2436264C (en) 2014-01-28
IL157071A0 (en) 2004-02-08
CN1250232C (zh) 2006-04-12
DE60222856T2 (de) 2008-07-24
AU2002250886B2 (en) 2007-08-02
JP5973701B2 (ja) 2016-08-23
NZ527493A (en) 2005-06-24
EA006397B1 (ru) 2005-12-29
EA200300862A1 (ru) 2003-12-25
US20040115178A1 (en) 2004-06-17
MXPA03007024A (es) 2003-11-18
NO20033372D0 (no) 2003-07-28
BR0207019A (pt) 2004-02-25
EP1359924A1 (de) 2003-11-12
KR20030076652A (ko) 2003-09-26
HK1066174A1 (en) 2005-03-18
CA2436264A1 (en) 2002-08-15
CN1501805A (zh) 2004-06-02
ES2292744T3 (es) 2008-03-16
NO20033372L (no) 2003-07-28
US7964384B2 (en) 2011-06-21
PT1359924E (pt) 2007-12-07
JP2014062104A (ja) 2014-04-10
JP2011246483A (ja) 2011-12-08
EP1359924B1 (de) 2007-10-10
ATE375164T1 (de) 2007-10-15
US20100136662A1 (en) 2010-06-03
WO2002062360A1 (en) 2002-08-15
ZA200306935B (en) 2004-12-06

Similar Documents

Publication Publication Date Title
DE60222856D1 (de) Endotoxin-bindung durch milchsäurebakterien und bifidobacteria
EP2343308A3 (de) Neuartige immunogene Zusammensetzungen zur Vorbeugung und Behandlung von Menginokokkenerkrankungen
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
EP3326634A3 (de) Zusammensetzung zur anregung der darmflora in neugeborenen, die durch kayserschnitt geboren wurden
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2005110445A3 (en) Methods and compositions for the dietary management of autoimmune disorders
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
BR0214705A (pt) Composição, seu uso, método para prevenção ou tratamento de doença neurodegenerativa, e kit
BR0214838A (pt) Composição para promoção de crescimento ósseo e manutenção da saúde óssea
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY148286A (en) Freeze-dried, aerated dairy or dairy-substitute compositions and methods of making thereof
SI2076271T1 (sl) Inhibicija toksinov kolere z galatooligosaharidi (GOS)
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
PT1328268E (pt) Combinacao de catequina e quercetina para utilizacao farmaceutica ou dietetica
BR0214902A (pt) Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos
EP2208734A4 (de) Nahrungsmittel zur inhibierung der osteoclastbildung
BRPI0409609A (pt) mediadores do transporte reverso de colesterol para o tratamento da hipercolesterolemia
WO2006129092A3 (en) Use of bacteriophage in medicaments
ATE458004T1 (de) Osteoprotegerin in milch
WO2009057282A1 (ja) 骨吸収抑制用食品素材
EA200802262A1 (ru) Назальные и буккальные композиции для борьбы с храпом
WO2003026693A3 (en) Inhibitors of costimulation by 0x40 and their use against infectious diseases
WO2007058934A3 (en) Methods and compositions for treating basement membrane disorders

Legal Events

Date Code Title Description
8363 Opposition against the patent